1983
Progress in cancer management. Keynote address
Devita V. Progress in cancer management. Keynote address. Cancer 1983, 51: 2401-2409. PMID: 6342749, DOI: 10.1002/1097-0142(19830615)51:12+<2401::aid-cncr2820511302>3.0.co;2-7.Peer-Reviewed Original ResearchConceptsCancer managementUtility of radiotherapyUse of radiotherapyCancer cure ratesWorld War IIEradication of cancerManagement of cancerPrime therapeutic targetFirst chemotherapyNational Cancer ActBlood transfusionLocal recurrenceMedical oncologistsTreatment failureRecurrent cancerCure rateWar IIEffective treatmentTherapeutic targetPatientsRadiotherapySurgerySuch toxicitySerious cancersCancer
1981
Erythrocyte osmotic fragility in patients receiving hyperthermia with and without chemotherapy.
Whang-Peng J, Lees D, Schuette W, Smith R, Bull J, DeVita V. Erythrocyte osmotic fragility in patients receiving hyperthermia with and without chemotherapy. Journal Of The National Cancer Institute 1981, 65: 1103-4. PMID: 7296555.Peer-Reviewed Original ResearchHigh-volume intraperitoneal chemotherapy with methotrexate in patients with cancer.
Jones R, Collins J, Myers C, Brooks A, Hubbard S, Balow J, Brennan M, Dedrick R, DeVita V. High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Research 1981, 41: 55-9. PMID: 7448776.Peer-Reviewed Original ResearchConceptsEpisodes of bacterial peritonitisNovel treatment modalitiesTotal body clearanceIntraperitoneal chemotherapyPeritoneal irritationChemotherapeutic regimensMethotrexate clearanceBacterial peritonitisOvarian cancerMalignant melanomaTreatment modalitiesLocal toxicitySystemic toxicityPlasma levelsPeritoneal cavitySystemic circulationTreatment cyclesPlasma concentrationsMethotrexate concentrationsTherapeutic benefitBody clearancePatientsMethotrexateChemotherapyPeritonitis
1979
Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects.
Weiss R, DeVita V. Multimodal primary cancer treatment (adjuvant chemotherapy): current results and future prospects. Annals Of Internal Medicine 1979, 91: 251-60. PMID: 380437, DOI: 10.7326/0003-4819-91-2-251.Peer-Reviewed Original ResearchConceptsDisease-free survivalPrimary treatment programGroup of patientsAdvanced diseaseTherapy regimensPrimary lesionSurgical removalAdult malignanciesPalliative treatmentTreatment resultsClinical trialsHuman trialsCancer mortalityChemotherapyMalignancyTreatment programsTreatmentRegimensPatientsLesionsCancer
1977
Malignant melanoma: prognostic factors and therapeutic results.
DeVita V, Fisher R. Malignant melanoma: prognostic factors and therapeutic results. West Virginia Medical Journal 1977, 73: 167-72. PMID: 268079.Peer-Reviewed Original Research
1976
Natural history of malignant melanoma as related to therapy.
DeVita V, Fisher R. Natural history of malignant melanoma as related to therapy. Journal Of The National Cancer Institute 1976, 60: 153-7. PMID: 1260773.Peer-Reviewed Original Research
1974
Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998)
Schein P, O'Connell M, Blom J, Hubbard S, Magrath I, Bergevin P, Wiernik P, Ziegler J, Devita V. Clinical antitumor activity and toxicity of streptozotocin (NSC‐85998). Cancer 1974, 34: 993-1000. PMID: 4371075, DOI: 10.1002/1097-0142(197410)34:4<993::aid-cncr2820340404>3.0.co;2-t.Peer-Reviewed Original ResearchConceptsMalignant carcinoid tumorsNormal renal functionIslet cell carcinomaClinical antitumor activityAcute lymphocytic leukemiaToxicity of streptozotocinHematologic toxicityAdvanced malignanciesRenal damageRenal functionCarcinoid tumorsHodgkin's diseaseCell carcinomaLymphocytic lymphomaTherapeutic responseLymphocytic leukemiaTumor massBurkitt's lymphomaDrug effectsMaximum dosesPatientsTotal doseStreptozotocinLymphomaAntitumor activityTreatment of malignant melanoma with methyl CCNU
Young R, Canellos G, Chabner B, Schein P, Brereton H, DeVita V. Treatment of malignant melanoma with methyl CCNU. Clinical Pharmacology & Therapeutics 1974, 15: 617-622. PMID: 4601745, DOI: 10.1002/cpt1974156617.Peer-Reviewed Original Research
1970
CELL CYCLE CHARACTERISTICS OF HUMAN SOLID TUMORS IN VIVO
Young R, DeVita V. CELL CYCLE CHARACTERISTICS OF HUMAN SOLID TUMORS IN VIVO. Cell Proliferation 1970, 3: 285-290. PMID: 5523056, DOI: 10.1111/j.1365-2184.1970.tb00273.x.Peer-Reviewed Original Research